168 related articles for article (PubMed ID: 20536646)
21. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
22. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
23. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
24. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
Li K; Huang CC; Randazzo B; Li S; Szapary P; Curran M; Campbell K; Brodmerkel C
J Invest Dermatol; 2016 Dec; 136(12):2364-2371. PubMed ID: 27476722
[TBL] [Abstract][Full Text] [Related]
25. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
Antiga E; Volpi W; Cardilicchia E; Maggi L; Filì L; Manuelli C; Parronchi P; Fabbri P; Caproni M
J Clin Immunol; 2012 Dec; 32(6):1221-32. PubMed ID: 22699761
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
Tan JY; Li S; Yang K; Ma B; Chen W; Zha C; Zhang J
J Dermatolog Treat; 2011 Dec; 22(6):323-36. PubMed ID: 20923370
[TBL] [Abstract][Full Text] [Related]
28. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris.
Niu X; Cao W; Ma H; Feng J; Li X; Zhang X
J Dermatol; 2012 Nov; 39(11):916-21. PubMed ID: 22913391
[TBL] [Abstract][Full Text] [Related]
29. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
31. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
Patsatsi A; Kyriakou A; Sotiriadis D
J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
[TBL] [Abstract][Full Text] [Related]
33. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.
Garcia-Valladares I; Cuchacovich R; Espinoza LR
Drug Des Devel Ther; 2011 Jan; 5():41-9. PubMed ID: 21267358
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
Zhu Y; Hu C; Lu M; Liao S; Marini JC; Yohrling J; Yeilding N; Davis HM; Zhou H
J Clin Pharmacol; 2009 Feb; 49(2):162-75. PubMed ID: 19179295
[TBL] [Abstract][Full Text] [Related]
35. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
36. Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients.
Rentenaar RJ; Heydendael VM; van Diepen FN; de Rie MA; ten Berge IJ
J Clin Immunol; 2004 Jul; 24(4):361-9. PubMed ID: 15163892
[TBL] [Abstract][Full Text] [Related]
37. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
38. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
[TBL] [Abstract][Full Text] [Related]
39. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
[TBL] [Abstract][Full Text] [Related]
40. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
